Marguerite Vignon

Dr. Marguerite Vignon


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Kidney International
Verified
Journal Article
Closed access
MVMarguerite Vignon
Marguerite Vignon
CCCamille Cohen
Camille Cohen
SFStanislas Faguer
Stanislas Faguer
LNLaure-Hélène Noel
Laure-Hélène Noel
CGCeline Guilbeau
Celine Guilbeau
FBFrank Bridoux
Frank Bridoux

16 December 2021 in Blood
Verified
Journal Article
Open access
PDF file
SHSoledad Henriquez
Soledad Henriquez
JZJérémie Zerbit
Jérémie Zerbit
TBTimothée Bruel
Timothée Bruel
AOAmani Ouedrani
Amani Ouedrani
DPDelphine Planas
Delphine Planas
MVMarguerite Vignon
Marguerite Vignon

27 October 2022 in Viruses
Verified
Journal Article
Open access
PDF file
JZJeremie Zerbit
Jeremie Zerbit
MDMarion Detroit
Marion Detroit
AMAntoine Meyer
Antoine Meyer
JDJustine Decroocq
Justine Decroocq
BDBenedicte Deau-Fischer
Benedicte Deau-Fischer
MVMarguerite Vignon
Marguerite Vignon
Background: Patients with hematological malignancies are at greater risk of severe COVID-19 and have been prioritized for COVID-19 vaccination. A significant proportion of them have an impaired vaccine response, both due to the underlying disease and to the treatments. Methods: We conducted a prospective observational study to identify the specific risks of the outpatient population with hematological diseases. Result: Between 22 December 2021 to 12 February 2022, we followed 338 patients of which 16.9% (n = 57) developed SARS-CoV-2 infection despite previous vaccination (94.7%). COVID-19 patients were more likely to have received immunotherapy (85.5% vs. 41%, p < 10−4), and particularly anti-CD20 monoclonal antibodies (40% vs. 14.9%, p < 10−4) and Bruton’s tyrosine kinase inhibitors (BTKi) (7.3% vs. 0.7%, p < 10−2). There was no significant difference in demographic characteristics or hematological malignancies between COVID-19-positive and non-positive patients. Patients hospitalized for COVID-19 had more frequently received immunotherapy than patients with asymptomatic or benign forms (100% vs. 77.3%, p < 0.05). Hospitalized COVID-19 patients had a higher proportion of negative or weakly positive serologies than non-hospitalized patients (92.3% vs. 61%, p < 0.05). Patients who received tixagevimab/cilgavimab prophylaxis (n = 102) were less likely to be COVID-19-positive (4.9 vs. 22%, p < 0.05) without significant difference in hospitalization rates. Conclusion: In the immunocompromised population of patients with hematological malignancies, the underlying treatment of blood cancer by immunotherapy appears to be a risk factor for SARS-CoV-2 infection and for developing a severe form.

27 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
GFGuillemette Fouquet
Guillemette Fouquet
MWMyriam Wartski
Myriam Wartski
ADAmina Dechmi
Amina Dechmi
LWLise Willems
Lise Willems
BDBénédicte Deau-Fischer
Bénédicte Deau-Fischer
ACAnne- Segolene Cottereau
Anne- Segolene Cottereau
Although anti-CD38 monoclonal antibodies have improved the prognosis of relapsed/refractory multiple myeloma (RRMM), some patients still experience early relapses with poor outcomes. This present study evaluated the predictive value of FDG PET/CT parameters for RRMM prior to initiating anti-CD38 treatment. We included 38 consecutive RRMM patients who underwent a PET/CT scan treated at our institution at relapse. The median PFS was 12.5 months and the median OS was not reached. 42% of the patients had an initial ISS score of 1, 37% of 2, and 21% of 3. The presence of >3 focal lesions (FLs, n = 19) and the ISS score were associated with inferior PFS (p = 0.0036 and p = 0.0026) and OS (p = 0.025 and p = 0.0098). Patients with >3 FLs had a higher initial ISS score (p = 0.028). In multivariable analysis, the ISS score and >3 FLs were independent prognostic factors for PFS (p = 0.010 and p = 0.025 respectively), and combined they individualized a high-risk group with a median PFS and OS of 3.1 months and 8.5 months respectively vs. not reached for the other patients. The presence of >3 FLs on PET was predictive of survival outcomes in patients with RRMM treated using CD38 targeted therapy. Combined with the initial ISS, an ultra-high-risk RRMM population can thus be identified.

11 September 2025 in Leukemia
Verified
Journal Article
Closed access
PDF file
BBBarbara Burroni
Barbara Burroni
SHStéphanie Harel
Stéphanie Harel
RSRaphaèle Seror
Raphaèle Seror
SASophia Ascione
Sophia Ascione
YKYoulia Kirova
Youlia Kirova
MVMarguerite Vignon
Marguerite Vignon

13 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
CBClaire Breal
Claire Breal
FBFrederic Beuvon
Frederic Beuvon
TWThibault de Witasse-Thezy
Thibault de Witasse-Thezy
SDSolène Dermine
Solène Dermine
PFPatricia Franchi-Rezgui
Patricia Franchi-Rezgui
MVMarguerite Vignon
Marguerite Vignon
The phosphatidylinositol 3-kinase (PI3K) pathway plays a key role in cancer progression and in host immunity. Idelalisib was the first of this class to be approved with the second-generation Pi3 kinase inhibitors copanlisib, duvelisib and umbralisib, subsequently being approved in the United States. Real-world data are lacking, however, in relation to the incidence and toxicity of Pi3 kinase inhibitor-induced colitis. We here review, in the first instance, the general landscape of the Pi3K inhibitors in the context of hematological malignancies, with a focus on the adverse gastrointestinal side effects reported by various clinical trials. We further review the available worldwide pharmacovigilance data in relation to these drugs. Finally, we describe our own real-world experience with idelalisib-induced colitis management in our center and in a national setting.